InsiderTrades.com logo
Ron Bentsur net worth and biography
  • LinkedIn
  • Phone
  • Website

Ron Bentsur Biography and Net Worth

CEO of Nuvectis Pharma

Ron Bentsur co-founded and has served as the Chairman, President and CEO of Nuvectis since 2020. He served as CEO of UroGen Pharma, Inc. (NASDAQ: URGN) from 2015 until 2019, and as CEO of Keryx Biopharmaceuticals, Inc. (acquired by Akebia Therapeutics) from 2009 until 2015. As CEO at UroGen and Keryx, Ron led the clinical development, regulatory approvals and the commercial infrastructure buildouts for the US commercial launches of Jelmyto and Auryxia, respectively. Ron also led the establishment of a successful worldwide partnership for an earlier-stage program at UroGen and an ex-US development partnership for Auryxia at Keryx. Prior to that, Ron served as CEO of XTL Biopharmaceuticals, Inc. (NASDAQ: XTLB) from 2006 until 2009 and as Investor Relations and CFO of Keryx from October 2000 until January 2006. Earlier in his career Ron worked as an investment banker in NYC and Tel Aviv, Israel, from 1994 until 2000. Ron also served as a member of the Board of Directors of Stemline Therapeutics, Inc. from 2009 through the approval and launch of Elzonris and the subsequent acquisition of the company by the Menarini Group in June 2020.

Ron holds a BA in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA (Magna Cum Laude), from New York University’s Stern School of Business.

What is Ron Bentsur's net worth?

The estimated net worth of Ron Bentsur is at least $68.12 million as of June 30th, 2026. Bentsur owns 3,688,424 shares of Nuvectis Pharma stock worth more than $68,117,814 as of July 14th. This net worth estimate does not reflect any other investments that Bentsur may own. Learn More about Ron Bentsur's net worth.

How do I contact Ron Bentsur?

The corporate mailing address for Bentsur and other Nuvectis Pharma executives is , , . Nuvectis Pharma can also be reached via phone at 201-614-3150. Learn More on Ron Bentsur's contact information.

Has Ron Bentsur been buying or selling shares of Nuvectis Pharma?

Ron Bentsur has not been actively trading shares of Nuvectis Pharma over the course of the past ninety days. Most recently, on Tuesday, June 30th, Ron Bentsur bought 12,500 shares of Nuvectis Pharma stock. The stock was acquired at an average cost of $20.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,688,424 shares of the company's stock, valued at $73,768,480. Learn More on Ron Bentsur's trading history.

Who are Nuvectis Pharma's active insiders?

Nuvectis Pharma's insider roster includes Ron Bentsur (CEO), Enrique Poradosu (Insider), and Juan Sanchez (Director). Learn More on Nuvectis Pharma's active insiders.

Are insiders buying or selling shares of Nuvectis Pharma?

In the last year, Nuvectis Pharma insiders bought shares 8 times. They purchased a total of 246,270 shares worth more than $2,291,193.18. The most recent insider tranaction occured on June, 30th when Major Shareholder Marlio Charles Mosseri bought 50,000 shares worth more than $916,000.00. Insiders at Nuvectis Pharma own 28.6% of the company. Learn More about insider trades at Nuvectis Pharma.

Information on this page was last updated on 6/30/2026.

Ron Bentsur Insider Trading History at Nuvectis Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/30/2026Buy12,500$20.00$250,000.003,688,424View SEC Filing Icon  
11/5/2025Buy5,000$5.72$28,600.003,525,924View SEC Filing Icon  
12/24/2024Buy4,500$4.65$20,925.003,270,924View SEC Filing Icon  
11/15/2024Buy20,000$4.92$98,400.003,266,424View SEC Filing Icon  
5/14/2024Buy1,940$6.74$13,075.603,246,424View SEC Filing Icon  
5/10/2024Buy2,000$6.40$12,800.003,244,484View SEC Filing Icon  
3/18/2024Buy5,000$10.29$51,450.003,242,484View SEC Filing Icon  
10/9/2023Buy830$11.19$9,287.703,236,844View SEC Filing Icon  
10/6/2023Buy250$11.27$2,817.503,236,014View SEC Filing Icon  
10/4/2023Buy1,820$10.95$19,929.003,234,364View SEC Filing Icon  
8/15/2023Buy235$14.34$3,369.903,232,429View SEC Filing Icon  
8/11/2023Buy180$14.66$2,638.803,232,194View SEC Filing Icon  
8/8/2023Buy120$14.83$1,779.603,232,014View SEC Filing Icon  
7/21/2023Buy225$14.85$3,341.253,231,894View SEC Filing Icon  
7/19/2023Buy200$14.33$2,866.003,231,559View SEC Filing Icon  
7/14/2023Buy150$15.03$2,254.503,231,359View SEC Filing Icon  
7/6/2023Buy320$14.88$4,761.603,231,099View SEC Filing Icon  
6/26/2023Buy750$16.50$12,375.003,230,779View SEC Filing Icon  
6/21/2023Buy500$17.88$8,940.003,230,029View SEC Filing Icon  
6/7/2023Buy230$17.41$4,004.303,229,409View SEC Filing Icon  
5/31/2023Buy330$17.28$5,702.403,229,179View SEC Filing Icon  
5/24/2023Buy200$17.49$3,498.003,228,849View SEC Filing Icon  
5/16/2023Buy320$17.02$5,446.403,228,649View SEC Filing Icon  
3/23/2023Buy230$12.13$2,789.903,228,329View SEC Filing Icon  
3/21/2023Buy480$12.08$5,798.403,228,099View SEC Filing Icon  
3/14/2023Buy1,680$10.85$18,228.003,227,139View SEC Filing Icon  
11/30/2022Buy150$7.45$1,117.503,015,459View SEC Filing Icon  
11/28/2022Buy150$7.40$1,110.003,015,159View SEC Filing Icon  
11/25/2022Buy150$7.38$1,107.003,015,009View SEC Filing Icon  
11/17/2022Buy250$7.24$1,810.003,014,359View SEC Filing Icon  
11/10/2022Buy1,000$7.07$7,070.003,014,109View SEC Filing Icon  
9/30/2022Buy500$7.46$3,730.003,013,109View SEC Filing Icon  
9/28/2022Buy500$7.23$3,615.003,012,609View SEC Filing Icon  
9/26/2022Buy500$7.69$3,845.003,012,109View SEC Filing Icon  
9/23/2022Buy1,000$7.93$7,930.003,011,609View SEC Filing Icon  
8/29/2022Buy1,000$9.07$9,070.003,008,909View SEC Filing Icon  
8/23/2022Buy500$9.00$4,500.003,007,909View SEC Filing Icon  
8/18/2022Buy14,426$8.58$123,775.083,002,409View SEC Filing Icon  
8/11/2022Buy19,669$8.40$165,219.602,987,983View SEC Filing Icon  
6/28/2022Buy300$11.82$3,546.002,964,614View SEC Filing Icon  
6/24/2022Buy400$12.18$4,872.002,964,314View SEC Filing Icon  
6/22/2022Buy100$13.10$1,310.002,963,714View SEC Filing Icon  
5/26/2022Buy500$15.90$7,950.002,963,114View SEC Filing Icon  
5/20/2022Buy1,000$16.28$16,280.002,962,614View SEC Filing Icon  
5/18/2022Buy1,700$19.36$32,912.002,961,414View SEC Filing Icon  
5/16/2022Buy1,000$19.32$19,320.002,959,404View SEC Filing Icon  
5/12/2022Buy12,245$16.99$208,042.552,957,704View SEC Filing Icon  
3/28/2022Buy4,000$7.05$28,200.00View SEC Filing Icon  
3/17/2022Buy7,000$7.63$53,410.00View SEC Filing Icon  
2/14/2022Buy8,000$5.88$47,040.00View SEC Filing Icon  
See Full Table

Ron Bentsur Buying and Selling Activity at Nuvectis Pharma

This chart shows Ron Bentsur's buying and selling at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Company Overview

Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More

Today's Range

Now: $18.52
Low: $18.28
High: $18.83

50 Day Range

MA: $13.93
Low: $9.31
High: $28.53

2 Week Range

Now: $18.52
Low: $5.55
High: $29.27

Volume

41,033 shs

Average Volume

152,773 shs

Market Capitalization

$491.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A